Results 11 to 20 of about 68,398 (251)
Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases [PDF]
Archive of Oncology, 2009 Out of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all ...
Pejčić Ivica, Vrbić Svetislav
doaj +3 more sources
CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells [PDF]
International Journal of Nanomedicine, 2016 Shuang Jiang,1,2,* Xiaobo Wang,2,* Zhiran Zhang,2 Lan Sun,3 Yunzhu Pu,3 Hongjuan Yao,3 Jingcao Li,3 Yan Liu,3 Yingge Zhang,3 Weijing Zhang1,4 1Department of Lymphoma, Affiliated Hospital of the Military Medical Academy of Sciences, Beijing, 2Department ...
Jiang S +9 more
doaj +1 more source
Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment [PDF]
European Medical Journal Oncology, 2013 Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of different haematological cancers with a wide range of aggressiveness. NHLs represent >80% of lymphomas and the majority of NHLs involve B cells.
Letizia Polito +4 more
doaj +2 more sources
ACR Open Rheumatology, 2022 Objective Patients with immune‐mediated diseases treated with anti‐CD20 monoclonal antibodies may have worse coronavirus disease 2019 (COVID‐19) outcomes due to impaired humoral immunity, but differences compared with the general population are unknown ...
Naomi J. Patel +12 more
doaj +1 more source
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
Brain Sciences, 2020 Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder.
Despoina Florou +4 more
doaj +1 more source
International Journal of Infectious Diseases, 2021 Prolonged B-cell depletion due to anti-CD20 monoclonal antibody (mAbs) therapy impairs the adaptive immune response, causing severe manifestations during COronaVIrus Disease-2019 (COVID-19).
Alessandra D’Abramo +8 more
doaj +1 more source
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies [PDF]
Current Opinion in Immunology, 2008 The anti-CD20, B-cell-specific mAb rituximab (RTX) has been approved for treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis. Under conditions of high B cell burden, exhaustion of the body's effector mechanisms, for example, NK-cell-mediated killing, may lead to substantial decreases in the immunotherapeutic efficacy of this mAb ...
Ronald P, Taylor, Margaret A, Lindorfer
openaire +2 more sources
Monoclonal antibody-based therapies for Waldenström's macroglobulinemia
Leukemia Research Reports, 2022 Monoclonal antibodies have established an important role in the treatment armamentarium of hematological malignancies, including Waldenström's macroglobulinemia.
Despina Fotiou +2 more
doaj +1 more source
Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product. [PDF]
Biologics, 2018 Sanjay Kumar Singh, Santosh Pokalwar, Sandip Bose, Shivika Gupta, Suhani Almal, Ranjit Sudhakar Ranbhor Sun Pharmaceutical Industries Limited, Tandalja, Vadodara 390 012, India Background: Cell surface protein, CD20, is extensively expressed on the ...
Singh SK +5 more
europepmc +2 more sources
Virulence, 2022 The optimal interval before receiving SARS-COV-2 vaccination for patients who have received anti-CD 20 monoclonal antibodies remains unclear. We considered original studies up to 29 October 2022 and conducted searches in Embase,Medrxiv, PubMed, and SSRN.
Kexin Liu, Jinyu Li, Gaosi Xu
doaj +1 more source